Who
Idan Elmelech
COO & Principal Financial Ofcr
Company insider
Files Form 4 as: COO & Principal Financial Ofcr, BridgeBio Oncology Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 10 May 2026
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,351343 at $3.94 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,675343 at $7.80 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,675343 at $7.80 | filing |
| 10 May 2026filed 12 May 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —758,222 at $0.00 | filing |
| 10 May 2026filed 12 May 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —758,222 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.